AS
Al-Batran, S-e.
1 yayın · 4 atıf · 2025–2025
Yayın
1
Atıf
4
Yıllar
1
Yayınlar
| Başlık | Yıl | Tip | Atıf |
|---|---|---|---|
|
Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma
|
2025 | Meeting Abstract | 4 |